

RPG LIFE SCIENCES LIMITED		
Regd. Office: RPG House, 463, Dr. Annie Besant Road, Worli, Mumbai 400 030.		
(Rs. In Lakhs)		
STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2017		
Particulars	3 months ended	
	30-06-2017	30-06-2016 (Refer note 2)
	Unaudited	
1. Revenue from Operations	7,851	8,259
2 Other Income	9	18
3 Total Income	7,860	8,277
4 Expenses		
(a) Cost of Materials Consumed	1,543	1,861
(b) Purchases of Stock-in-Trade	1,006	1,786
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(179)	(720)
(d) Excise Duty Paid	234	312
(e) Employee Benefits Expense	2,042	1,687
(f) Finance Costs	96	40
(g) Depreciation and Amortisation Expense	348	224
(h) Other Expenses	2,723	2,285
4 Total Expenses	7,813	7,475
5 Profit before tax from continuing operations	47	802
6 Income tax expenses		
a. Current Tax	10	213
b. Deferred Tax	(6)	(213)
7 Profit from continuing operations	43	802
8 Profit from discontinued operations before tax	-	147
9 Tax expenses of discontinued operations	-	-
10 Profit from discontinued operations	-	147
11 Profit for the period	43	949
12 Other Comprehensive Income		
(i) Items that will not be reclassified to Profit or Loss	(23)	(23)
(ii) Income tax relating to items that will not be reclassified to Profit or Loss	-	-
Other Comprehensive Income Net of Tax	(23)	(23)
13 Total Comprehensive Income for the period	20	926
14. Paid-up Equity Share Capital (Face Value Rs. 8 each)	1,323	1,323
15. Earnings per Share form discontinued operations (of Rs. 8 each) (not annualised):		
(a) Basic	-	0.89
(b) Diluted	-	0.89
Earnings per Share form continuing operations (of Rs. 8 each) (not annualised):		
(a) Basic	0.26	4.85
(b) Diluted	0.26	4.85

Notes:

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 4, 2017. The Statutory Auditors of the Company have conducted a 'Limited Review' of the above Unaudited Financial Results for the quarter ended June 30,2017.
- On April 1, 2017 the Company has adopted the Indian Accounting Standards ('Ind AS') notified by the Ministry of Corporate Affairs with effect from April 1 ,2016. Accordingly, the financial results for the quarter ended June 30,2017 have been prepared in accordance with Ind AS and other accounting principles generally accepted in India and the results for the comparative quarter ended June 30, 2016 have been restated in accordance with Ind AS. The financial results for the quarter ended June 30, 2016 have not been reviewed or audited by the auditors and are compiled by the management after exercising necessary due diligence to ensure that these give a true and fair view of the Company's affairs.
- The Company operates in only one reportable business segment i.e., Pharmaceuticals.
- Reconciliation of results between previous reported (referred to previous GAAP) and Ind AS for the quarter ended June 30, 2016 is presented as below:

		Rs. In Lakhs
Profit for quarter ended June 30, 2016 as per previous GAAP		987
Re-measurement of revenue	(a)	(61)
Re-measurement of Employee Benefit Net of tax	(b)	23
Other Comprehensive Income Net of Tax		949
Re-measurement of Employee Benefit Net of tax		(23)
Total Comprehensive Income for the period		926

Profit reconciliation Notes

- Provision for sales return has been made under Ind AS as per past trend of sales return to sales.
- The re-measurement cost arising primarily due to changes in actuarial assumptions have been recognised in Other Comprehensive Income under Ind AS as compared to Statement of Profit or Loss under Previous GAAP.

5. In the corresponding quarter ended June 30,2016, pursuant to the approval of the Board of Directors at their meeting held on May 26, 2016, the Company had entered into a Business Transfer Agreement dated May 26, 2016 with Intas Pharmaceuticals Limited for sale of its Biotech Business Unit, as a going concern on a slump sale basis. The same has been considered as a discontinuing operation in June 2016, in accordance with Ind AS - 105 - "Non-current Assets held for sale and Discontinued Operations" and the requisite information for Biotech Business Unit has been furnished hereunder;

Particulars	(Rs. In Lakhs)	
	30-06-2017	30-06-2016
	Unaudited	
a) Revenue from Operations	-	661
b) Direct Expenses	-	514
c) Profit from ordinary activities before tax	-	147
d) Tax Expense (net off MAT Credit Entitlement)	-	-
e) Net Profit	-	147

6. There are no exceptional items.
7. The statement does not include Ind AS compliant results for the preceding quarter and previous year ended March 31, 2017 as the same is not mandatory as per SEBI's circular dated July 5, 2016

For RPG Life Sciences Limited

CT. Renganathan
 Managing Director
 DIN - 02158397
 Mumbai, August 4, 2017